Screener
Neurocrine Biosciences NBIX Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's current ratio?
- Neurocrine Biosciences (NBIX) reported current ratio of 2.9× in Q1 2026.
- How has Neurocrine Biosciences's current ratio changed year-over-year?
- Neurocrine Biosciences's current ratio decreased by 6.5% year-over-year, from 3.1× to 2.9×.
- What is the long-term trend for Neurocrine Biosciences's current ratio?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's current ratio has grown at a -9.0% compound annual growth rate (CAGR), from 5.4× to 3.4×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about Neurocrine Biosciences's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude